January 4, 2018 / 1:45 PM / a year ago

BRIEF-Revance Provides Update On Anticipated Clinical Milestones And Financial Outlook For 2018

Jan 4 (Reuters) - Revance Therapeutics Inc:

* REVANCE PROVIDES UPDATE ON ANTICIPATED CLINICAL MILESTONES AND FINANCIAL OUTLOOK FOR 2018

* REVANCE THERAPEUTICS INC - EXPECTS TO COMPLETE RT002 SAKURA PHASE 3 PROGRAM AND START RT002 PHASE 3 TRIAL FOR CERVICAL DYSTONIA IN 2018

* REVANCE THERAPEUTICS INC - EXPECTS CASH BURN FOR 2018 TO BE IN RANGE OF $117 TO $137 MILLION

* REVANCE THERAPEUTICS INC - ANTICIPATES 2018 GAAP RESEARCH AND DEVELOPMENT EXPENSE TO BE IN RANGE OF $84 TO $101 MILLION Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below